Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on April 7, 2022. The filing discloses the entry into a new material definitive agreement regarding an equity offering and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- New Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $26,000,000 under a new Open Market Sale Agreement with Jefferies LLC.
- Agent Compensation: The Company agreed to pay Jefferies LLC commissions of up to 3.0% of the gross proceeds from the sale of shares.
- Prior Agreement Performance: Under the terminated agreement with Cantor Fitzgerald & Co., the Company sold an aggregate of 21,532,665 shares for gross proceeds of $74.7 million.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these operational financial indicators.
Material Changes Versus Prior Period
The primary material change is the replacement of the sales agent for the Company's "at-the-market" equity offering program. On March 16, 2022, the Company terminated its Controlled Equity Offering Amended and Restated Sales Agreement with Cantor Fitzgerald & Co. On April 7, 2022, the Company entered into a new Open Market Sale Agreement with Jefferies LLC to continue the offering of shares up to the remaining capacity of the prior program.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company intends to utilize the new agreement to sell shares from time to time through Jefferies LLC as agent. The offering may be suspended or terminated by either party upon notice.
Risks and Contingencies: The sale of shares is subject to market conditions and the terms of the Sales Agreement. The filing includes standard legal disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Important Facts for Investor Verification
- Verify the current share price and potential dilution impact of the $26 million offering capacity.
- Confirm the remaining cash balance and burn rate, as this equity offering is likely intended to fund operations.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check subsequent filings to determine if and when shares have actually been sold under the new Jefferies agreement.